Statistiche di base
| CIK | 1527352 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Nexalin Technology, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-41507 NEXALIN TECHNOLOGY, |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 1, 2025 NEXALIN TECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-41507 27-5566468 (State or other jurisdiction of incorporation) (Commission |
|
| August 4, 2025 |
Exhibit 99.1 Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin’s Next Phase of Growth and Strategic Initiatives HOUSTON – August 1, 2025 – Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the appointment of Justin Van Fleet, |
|
| July 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 17, 2025 NEXALIN TECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-41507 27-5566468 (State or other jurisdiction of incorporation) (Commission |
|
| July 21, 2025 |
Employment Agreement between the Company and Justin Van Fleet dated as of July 21, 2025 Exhibit 10.1 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (this “Agreement”) dated as of July 17, 2025, by and between justin van fleet (the “Executive”) and NEXALIN TECHNOLOGY INC. (the “Company”). WHEREAS, the Company would like to employ the Executive as its Chief Financial Officer; and WHEREAS, the Company and the Executive desire to provide for the terms and conditions of the future employment o |
|
| July 17, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 16, 2025 NEXALIN TECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-41507 27-5566468 (State or other jurisdiction of incorporation) (Commission |
|
| June 17, 2025 |
NEXALIN TECHNOLOGY, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ |
|
| June 9, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 6, 2025 NEXALIN TECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-41507 27-5566468 (State or other jurisdiction of incorporation) (Commission F |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-41507 NEXALIN TECHNOLOGY, |
|
| May 6, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 4, 2025 NEXALIN TECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-41507 27-5566468 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 6, 2025 |
Underwriting Agreement dated May 4, 2025 between the Company and Maxim Group LLC Exhibit 10.1 UNDERWRITING AGREEMENT May 4, 2025 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Nexalin Technology, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, (this “Agreement”), to sell to you, Maxim Group LLC (“Maxim” or the “Representative”) as representative of the underwriters listed on Sch |
|
| May 6, 2025 |
Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock Exhibit 99.1 Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock HOUSTON, TX, May 5, 2025 — Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the pricing of an underwritten public offering of 3,850,000 shares of its common stock at a price to the pu |
|
| May 6, 2025 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-286711 PROSPECTUS SUPPLEMENT (To the Prospectus dated April 23, 2025) 3,850,000 Shares of Common Stock NEXALIN TECHNOLOGY, INC. We are offering under this prospectus supplement 3,850,000 shares of our common stock, par value $0.001 per share, at a price of $1.30 per share. Our common stock is traded on The Nasdaq Capital Market under the symbol |
|
| May 5, 2025 |
Amendment No. 1 to Equity Distribution Agreement Exhibit 10.1 NEXALIN TECHNOLOGY, INC. AMENDMENT NO. 1 TO EQUITY DISTRIBUTION AGREEMENT May 5, 2025 Maxim Group LLC 300 Park Avenue, 16th Floor New York, New York 10022 Ladies and Gentlemen: This Amendment No. 1, dated May 5, 2025 (the “Amendment”) to the Equity Distribution Agreement, dated April 23, 2025, (the “Equity Distribution Agreement”), is entered into by and among Nexalin Technology, Inc. |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 5, 2025 NEXALIN TECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-41507 27-5566468 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 5, 2025 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-286711 PROSPECTUS SUPPLEMENT (to the Prospectus dated April 23, 2025) Up to $3,100,000 NEXALIN TECHNOLOGY, INC. Common Stock On April 23, 2025, we entered into an Equity Distribution Agreement (the “ATM Sales Agreement”) with Maxim Group LLC (the “Sales Agent”), relating to shares of our common stock, par value $0.001 per share. In accordance w |
|
| May 2, 2025 |
PRELIMINARY PROSPECTUS SUPPLEMENT (To the Prospectus dated April 23, 2025) Filed Pursuant to Rule 424(b)(4) Registration No. 333-286711 The information in this preliminary prospectus supplement and the accompanying prospectus, relating to an effective registration statement under the Securities Act of 1933, as amended, is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and w |
|
| April 28, 2025 |
1776 Yorktown, Suite 550 Houston, Texas 77056 1776 Yorktown, Suite 550 Houston, Texas 77056 April 28, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. |
|
| April 23, 2025 |
S-3 1 nexalins3.htm S-3 Registration No. [ ]-[ ] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NEXALIN TECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 3845 27-5566468 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Co |
|
| April 23, 2025 |
EX-FILING FEES 6 nexalinex107.htm EXHIBIT 107 Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Nexalin Technology, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Pro |
|
| April 23, 2025 |
Equity Distribution Agreement between the Company and Maxim Group LLC EX-1.2 2 nexalinex1-2.htm EXHIBIT 1.2 Exhibit 1.2 NEXALIN TECHNOLOGY, INC. Up to $9,777,825 of Common Stock equity distribution AGREEMENT April 23, 2025 Maxim Group LLC 300 Park Avenue, 16th Floor New York, New York 10022 Ladies and Gentlemen: Nexalin Technology, Inc., a Delaware corporation headquartered in Houston, Texas (the “Company”), proposes to issue and sell through or to Maxim Group LLC, |
|
| April 17, 2025 |
Letter from Marcum LLP dated April 17, 2025 Exhibit 16.1 April 17, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Nexalin Technology, Inc. under Item 4.01 of its Form 8-K dated April 16, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Nexalin Technology, Inc. cont |
|
| April 17, 2025 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 16, 2025 NEXALIN TECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-41507 27-5566468 (State or other jurisdiction of incorporation) (Commission |
|
| April 15, 2025 |
Nexalin Technology, Inc. Compensation Recoupment Policy Exhibit 97.1 Nexalin Technology, Inc. Compensation Recoupment Policy Section 1. Purpose. Nexalin Technology, Inc. (the “Company”) has adopted this Compensation Recoupment Policy (this “Policy”) to implement a mandatory clawback policy in the event of a Restatement in compliance with the applicable rules of the Nasdaq exchange or any other securities exchange or inter-dealer quotation service on wh |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-41507 NEXALI |
|
| April 15, 2025 |
Nexalin Technology, Inc. Insider Trading Policy Exhibit 19.1 NEXALIN TECHNOLOGY, INC. INSIDER TRADING POLICY The Board of Directors (the “Board”) of Nexalin Technology, Inc., a Delaware corporation (the “Company”), has adopted the following updated Insider Trading Policy (the “Policy”). I. APPLICABILITY OF POLICY; DEFINITION OF INSIDER This Policy applies to all transactions in the Company’s securities, including common stock, options and warra |
|
| April 10, 2025 |
Warshaw Burstein, LLP 575 Lexington Avenue New York, NY 10022 (212) 984-7700 Confidential VIA EDGAR April 10, 2025 Division of Corporation Finance Office of Industrial Applications and Services United States Securities and Exchange Commission 100 F. |
|
| March 31, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Nexalin Technology, Inc. |
|
| March 31, 2025 |
NEXALIN TECHNOLOGY, INC. Up to $13,421,958 of Common Stock equity distribution AGREEMENT Exhibit 1.2 NEXALIN TECHNOLOGY, INC. Up to $13,421,958 of Common Stock equity distribution AGREEMENT March 31, 2025 Maxim Group LLC 300 Park Avenue, 16th Floor New York, New York 10022 Ladies and Gentlemen: Nexalin Technology, Inc., a Delaware corporation headquartered in Houston, Texas (the “Company”), proposes to issue and sell through or to Maxim Group LLC, as exclusive sales agent (the “Agent” |
|
| March 31, 2025 |
As confidentially submitted to the Securities and Exchange Commission on March 31, 2025. |
|
| March 31, 2025 |
NEXALIN TECHNOLOGY, INC. INSIDER TRADING POLICY Adopted March 31, 2025 Exhibit 19.1 NEXALIN TECHNOLOGY, INC. INSIDER TRADING POLICY Adopted March 31, 2025 The Board of Directors (the “Board”) of Nexalin Technology, Inc., a Delaware corporation (the “Company”), has adopted the following updated Insider Trading Policy (the “Policy”). I. APPLICABILITY OF POLICY; DEFINITION OF INSIDER This Policy applies to all transactions in the Company’s securities, including common s |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-41507 NEXALIN TECHNOLOGY, INC. |
|
| February 6, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 3, 2025 NEXALIN TECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-41507 27-5566468 (State or other jurisdiction of incorporation) (Commissi |
|
| January 30, 2025 |
As filed with the Securities and Exchange Commission on January 30, 2025 As filed with the Securities and Exchange Commission on January 30, 2025 Registration No. |
|
| January 30, 2025 |
1776 Yorktown, Suite 550 Houston, Texas 77056 1776 Yorktown, Suite 550 Houston, Texas 77056 January 30, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. |
|
| January 10, 2025 |
As filed with the Securities and Exchange Commission on January 10, 2025 As filed with the Securities and Exchange Commission on January 10, 2025 Registration No. |
|
| December 20, 2024 |
Supplier Quality Agreement dated as of December 20, 2024 between the Company and Velentium Exhibit 10.19 Title: SUPPLIER QUALITY AGREEMENT Document # SOP 013-F3 Revision A ECO # 001 Effective Date 20 Dec 2024 Page 1 of 5 SUPPLIER QUALITY AGREEMENT This agreement is entered into by Nexalin Technology Inc. a Delaware corporation, with its principal place of business at 1776 Yorktown, Suite 550A, Houston, TX 77056 (“Company”) and Velentium, with its principal place of business at 7535 W Gr |
|
| December 20, 2024 |
As filed with the Securities and Exchange Commission on December 20, 2024 As filed with the Securities and Exchange Commission on December 20, 2024 Registration No. |
|
| December 20, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Nexalin Technology, Inc. |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-41507 NEXALIN TECHNOL |
|
| November 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 1, 2024 NEXALIN TECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-41507 27-5566468 (State or other jurisdiction of incorporation) (Commissi |
|
| November 1, 2024 |
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements Exhibit 99.1 Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements HOUSTON, TEXAS, November 1, 2024 – Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced that the Company received notice from The Nasdaq Stock Market (“Nasdaq”) on October 31, 2024, notifying the Company that it has regained compliance with Nasdaq’s minimum bid price requir |
|
| September 25, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 23, 2024 NEXALIN TECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-41507 27-5566468 (State or other jurisdiction of incorporation) (Commis |
|
| September 19, 2024 |
Letter Agreement between the Company and Carolyn Shelton Exhibit 10.1 1776 Yorktown, Suite 550 Houston, Texas 77056 September 3, 2024 Ms. Carolyn Shelton Re: Terms of Employment Dear Carolyn, We are very excited at the prospect of your joining Nexalin Technology, Inc. (the “Company”). Our offer of employment is for the position listed below and is subject to the following terms and conditions: 1. Title/Position. Senior Vice President Quality, Regulatory |
|
| September 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 16, 2024 NEXALIN TECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-41507 27-5566468 (State or other jurisdiction of incorporation) (Commis |
|
| September 3, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 26, 2024 NEXALIN TECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-41507 27-5566468 (State or other jurisdiction of incorporation) (Commissio |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-41507 NEXALIN TECHNOLOGY, |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 29, 2024 NEXALIN TECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-41507 27-5566468 (State or other jurisdiction of incorporation) (Commission |
|
| July 29, 2024 |
NEXALIN TECHNOLOGY, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ |
|
| July 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 16, 2024 NEXALIN TECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-41507 27-5566468 (State or other jurisdiction of incorporation) (Commission |
|
| July 3, 2024 |
Nexalin Technology Announces Closing of $5.2 Million Public Offering Exhibit 99.1 Nexalin Technology Announces Closing of $5.2 Million Public Offering HOUSTON, July 1, 2024 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced the closing of its previously announced public offering of 3,000,000 shares of common stock at public offering price of $1.75. Gross proceeds, before deducting placement agent fees and o |
|
| July 3, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 2, 2024 NEXALIN TECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-41507 27-5566468 (State or other jurisdiction of incorporation) (Commission F |
|
| July 1, 2024 |
PROSPECTUS NEXALIN TECHNOLOGY, INC. $5,250,000 of Common Stock Filed pursuant to Rule 424b4(2) Registration No. 333-279684 PROSPECTUS NEXALIN TECHNOLOGY, INC. $5,250,000 of Common Stock We are offering $5,250,000 of our common stock, $0.001 par value per share. We are offering each share of common stock at a public offering price of $1.75 per share. We have engaged Maxim Group LLC (the “Placement Agent” or “Maxim”), to act as our exclusive placement agent in |
|
| June 28, 2024 |
Nexalin Technology Announces Pricing of $5.2 Million Public Offering Exhibit 99.1 Nexalin Technology Announces Pricing of $5.2 Million Public Offering HOUSTON, June 27, 2024 (GLOBE NEWSWIRE) - Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced the pricing of a public offering of 3,000,000 shares of common stock at public offering price of $1.75. Gross proceeds, before deducting placement agent fees and other offering expenses |
|
| June 28, 2024 |
Exhibit 10.1 PLACEMENT AGENCY AGREEMENT June 27, 2024 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), Nexalin Technology, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of 3,000,000 shares (the “Shares”) of the Company’s common stock, $0.001 par value per shar |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 27, 2024 NEXALIN TECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-41507 27-5566468 (State or other jurisdiction of incorporation) (Commission |
|
| June 26, 2024 |
Exhibit 10.15 Form of Lock-Up Agreement , 2024 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: The undersigned understands that Maxim Group LLC (the “Placement Agent”) proposes to enter into a placement agency agreement (the “Placement Agency Agreement”) with Nexalin Technology, Inc., a Delaware corporation (the “Company”), providing, on a “reasonable best effo |
|
| June 26, 2024 |
[Signature Page to Underwriters Acceleration Request] June 26, 2024 VIA EDGAR Robert Augustin Jane Park Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N. |
|
| June 26, 2024 |
1776 Yorktown, Suite 550 Houston, Texas 77056 1776 Yorktown, Suite 550 Houston, Texas 77056 June 26, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. |
|
| June 26, 2024 |
Form of Securities Purchase Agreement Exhibit 10.16 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [●], 2024, between Nexalin Technology, Inc. (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in this Agreemen |
|
| June 26, 2024 |
Exhibit 1.2 PLACEMENT AGENCY AGREEMENT June [ ], 2024 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), Nexalin Technology, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Co |
|
| June 26, 2024 |
As filed with the Securities and Exchange Commission on June 26, 2024 As filed with the Securities and Exchange Commission on June 26, 2024 Registration No. |
|
| June 24, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Nexalin Technology, Inc. |
|
| June 24, 2024 |
Form of Placement Agency Agreement between the Company and Maxim Group LLC Exhibit 1.2 PLACEMENT AGENCY AGREEMENT June [ ], 2024 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), Nexalin Technology, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Co |
|
| June 24, 2024 |
Exhibit 10.15 Form of Lock-Up Agreement , 2024 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: The undersigned understands that Maxim Group LLC (the “Placement Agent”) proposes to enter into a placement agency agreement (the “Placement Agency Agreement”) with Nexalin Technology, Inc., a Delaware corporation (the “Company”), providing, on a “reasonable best effo |
|
| June 24, 2024 |
As filed with the Securities and Exchange Commission on June 24, 2024 As filed with the Securities and Exchange Commission on June 24, 2024 Registration No. |
|
| June 24, 2024 |
WARSHAW BURSTEIN, LLP 575 Lexington Avenue New York, NY 10022 Telephone: 212-984-7700 www. |
|
| June 24, 2024 |
Form of Securities Purchase Agreement Exhibit 10.16 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [●], 2024, between Nexalin Technology, Inc. (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in this Agreemen |
|
| June 18, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 13, 2024 NEXALIN TECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-41507 27-5566468 (State or other jurisdiction of incorporation) (Commission |
|
| June 18, 2024 |
Exhibit 99.1 Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa) June 13, 2024 3:00 PM Brazil represents the 9th largest economy in the world with more than 35 million afflicted by mental health disorders HOUSTON, TX, June 13, 2024 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (the “Company” or “Ne |
|
| June 14, 2024 |
Exhibit 10.15 Form of Lock-Up Agreement , 2024 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: The undersigned understands that Maxim Group LLC (the “Placement Agent”) proposes to enter into a placement agency agreement (the “Placement Agency Agreement”) with Nexalin Technology, Inc., a Delaware corporation (the “Company”), providing, on a “reasonable best effo |
|
| June 14, 2024 |
As filed with the Securities and Exchange Commission on June 14, 2024 As filed with the Securities and Exchange Commission on June 14, 2024 Registration No. |
|
| June 14, 2024 |
Form of Securities Purchase Agreement Exhibit 10.16 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [●], 2024, between Nexalin Technology, Inc. (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in this Agreemen |
|
| June 14, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Nexalin Technology, Inc. |
|
| June 14, 2024 |
Form of Placement Agency Agreement between the Company and Maxim Group LLC Exhibit 1.2 PLACEMENT AGENCY AGREEMENT June [ ], 2024 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), Nexalin Technology, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Co |
|
| June 12, 2024 |
WARSHAW BURSTEIN, LLP 575 Lexington Avenue New York, NY 10022 Telephone: 212-984-7700 www. |
|
| May 23, 2024 |
As filed with the Securities and Exchange Commission on May 23, 2024 As filed with the Securities and Exchange Commission on May 23, 2024 Registration No. |
|
| May 23, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Nexalin Technology, Inc. |
|
| May 21, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 16, 2024 NEXALIN TECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-41507 27-5566468 (State or other jurisdiction of incorporation) (Commission F |
|
| May 14, 2024 |
1776 Yorktown Suite 550 Houston, TX 77056 1776 Yorktown Suite 550 Houston, TX 77056 May 14, 2024 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-41507 NEXALIN TECHNOLOGY, |
|
| April 26, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 25, 2024 NEXALIN TECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-41507 27-5566468 (State or other jurisdiction of incorporation) (Commission |
|
| April 26, 2024 |
Nexalin Techn ology Regains Compliance with Nasdaq Continued Listing Requirements Exhibit 99.1 Nexalin Techn ology Regains Compliance with Nasdaq Continued Listing Requirements HOUSTON, TEXAS, April 25, 2024 (GLOBE NEWSWIRE) - Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced that the Company received notice from The Nasdaq Stock Market (“Nasdaq”) on April 23, 2024, notifying the Company that it has regained compliance with Nasdaq’s minimum bi |
|
| April 16, 2024 |
Form of Equity Distribution Agreement between the Company and Maxim Group LLC Exhibit 1.2 NEXALIN TECHNOLOGY, INC. Up to [●] Shares of Common Stock EQUITY DISTRIBUTION AGREEMENT April [●], 2024 Maxim Group LLC 300 Park Avenue, 16th Floor New York, New York 10022 Ladies and Gentlemen: Nexalin Technology, Inc., a Delaware corporation (the “Company”), proposes to issue and sell through Maxim Group LLC (the “Agent”), as exclusive sales agent, shares of common stock, par value $ |
|
| April 16, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Nexalin Technology, Inc. |
|
| April 16, 2024 |
As filed with the Securities and Exchange Commission on April 15, 2024 As filed with the Securities and Exchange Commission on April 15, 2024 Registration No. |
|
| April 11, 2024 |
Exhibit 99.1 Nexalin Technology CEO Provides Letter to Shareholders Reports on growing clinical data supporting its neurostimulation technology and progress advancing its new Gen-3 HALO™ Clarity Virtual Clinic model HOUSTON, TEXAS, April 10, 2024 – Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today provided the following letter to shareholders from the Company’s CEO, |
|
| April 11, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 10, 2024 NEXALIN TECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-41507 27-5566468 (State or other jurisdiction of incorporation) (Commission |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-41507 NEXALIN TECHNOLOGY, INC. |
|
| March 20, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 7, 2024 NEXALIN TECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-41507 27-5566468 (State or other jurisdiction of incorporation) (Commission |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2023 NEXALIN TECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-41507 27-5566468 (State or other jurisdiction of incorporation) (Commissi |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-41507 NEXALIN TECHNOL |
|
| October 6, 2023 |
NEXALIN TECHNOLOGY, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ |
|
| September 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 21, 2023 NEXALIN TECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-41507 27-5566468 (State or other jurisdiction of incorporation) (Commis |
|
| August 10, 2023 |
Employment Agreement between the Company and Michael Nketiah dated as of July 1, 2023. Exhibit 10.11 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (this “Agreement”) dated as of July 1, 2023 (the “Effective Date”), by and between MICHAEL NKETIAH (the “Executive”) and NEXALIN TECHNOLOGY, INC. (the “Company”). WHEREAS, the Company has offered the Executive employment on the terms set out in this Agreement, and the Executive has accepted the Company’s offer, effective as of the Effective D |
|
| August 10, 2023 |
Employment Agreement between the Company and Mark White dated as of July 1, 2023. Exhibit 10.2 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (this “Agreement”) dated as of July 1, 2023 (“Effective Date”) between MARK WHITE (the “Executive”) and NEXALIN TECHNOLOGY INC. (the “Company”). WHEREAS, the Company and Executive have previously entered into an Employment Agreement dated as of February 15, 2021 (“February 2021 Agreement”) whereby the Executive and the Company delineated the t |
|
| August 10, 2023 |
Services Agreement between the Company and David Owens, M.D. dated as of July 1, 2023. Exhibit 10.3 SERVICES AGREEMENT SERVICES AGREEMENT (this “Agreement”) dated as of July 1, 2023 (the “Effective Date”) between DAVID OWENS, M.D. (the “Consultant”) and NEXALIN TECHNOLOGY, INC. (the “Company”). WHEREAS, the Company and the Consultant have previously entered into that certain Agreement dated as of February 15, 2021, as amended by that certain Amendment No. 1 to such agreement, dated |
|
| August 10, 2023 |
Joint Venture Agreement between the Company and Wider Come Limited dated as of May 31, 2023. Exhibit 10.1 JOINT VENTURE AGREEMENT JOINT VENTURE AGREEMENT (this “Agreement”) dated as of May 31, 2023 (the “Effective Date”), by and between Nexalin Technology, Inc., a Nevada corporation (“Nexalin”), and Wider Come Limited, a company formed under the laws of the People’s Republic of China (“Wider”, and together with Nexalin, collectively, the “parties” and each, a “party”). RECITALS: WHEREAS, |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-41507 NEXALIN TECHNOLOGY, |
|
| June 2, 2023 |
Exhibit 99.1 Nexalin Technology, Inc. and Wider Come Limited Announce Joint Venture Agreement to Advance Commercialization of Nexalin’s tACS Devices in the Asia Pacific Region Wider Come to fund and conduct a total of four clinical trials, spanning insomnia, depression and other indications HOUSTON, TEXAS, June 1, 2023 – Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) to |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 31, 2023 NEXALIN TECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-41507 27-5566468 (State or other jurisdiction of incorporation) (Commission F |
|
| May 16, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 10, 2023 NEXALIN TECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-41507 27-5566468 (State or other jurisdiction of incorporation) (Commission F |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-41507 NEXALIN TECHNOLOGY, |
|
| May 10, 2023 |
Amended and Restated Promissory Note in favor of Mark White dated as of January 1, 2023. Exhibit 10.14 AMENDED AND RESTATED PROMISSORY NOTE As of January 1, 2023 $200,000 For Value Received, NEXALIN TECHNOLOGY, INC., a Delaware corporation (the “Maker”) promises to pay to the order of MARK WHITE (the “Payee”) the principal sum of TWO HUNDRED THOUSAND DOLLARS ($200,000) (the “Loan”). The entire unpaid balance and interest thereon of the Loan as set forth below shall be due and payable |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-41507 NEXALIN TECHNOLOGY, INC. |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-41507 NEXALIN TECHNOL |
|
| October 3, 2022 |
Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 30, 2022 NEXALIN TECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-41507 27-5566468 (State or other jurisdiction of incorporation) (Commis |
|
| October 3, 2022 |
Letter from Friedman LLP dated as of September 30, 2022 Exhibit 16.1 September 30, 2022 Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Commissioners: We have read the statements made by Nexalin Technology, Inc. under Item 4.01 of its Form 8-K dated September 30, 2022. We agree with the statements concerning our firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Nexalin Technology, I |
|
| September 20, 2022 |
Underwriting Agreement dated as of September 15, 2022 between the Registrant and Maxim Group LLC Exhibit 4.1 EXECUTION COMMON STOCK PURCHASE WARRANT AGREEMENT Nexalin technology, inc. THIS COMMON STOCK PURCHASE WARRANT AGREEMENT (the ?Warrant?) dated as of September 16, 2022 is entered into by and between NEXALIN TECHNOLOGY INC., a Delaware corporation (the ?Company?), and Continental Stock Transfer & Trust Company, a New York corporation (the ?Warrant Agent?). WHEREAS, the Company has filed |
|
| September 20, 2022 |
Other Events, Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K/A 1 nexalintech8ka1.htm 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 20, 2022 NEXALIN TECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-41507 27-5566468 (State or other ju |
|
| September 20, 2022 |
Other Events, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 20, 2022 NEXALIN TECHNOLGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-41507 27-5566468 (State or other jurisdiction of incorporation) (Commiss |
|
| September 20, 2022 |
Nexalin Technology, Inc. Announces Closing of $9.6 Million Initial Public Offering Exhibit 99.1 Nexalin Technology, Inc. Announces Closing of $9.6 Million Initial Public Offering HOUSTON, TEXAS, September 19, 2022 – Nexalin Technology, Inc. (the “Company” or “Nexalin”) today announced the closing of its previously announced initial public offering of 2,315,000 units consisting of 2,315,000 shares of its common stock and 2,315,000 accompanying warrants to purchase 2,315,000 share |
|
| September 20, 2022 |
Nexalin Technology, Inc. Announces Closing of $9.6 Million Initial Public Offering Exhibit 99.1 Nexalin Technology, Inc. Announces Closing of $9.6 Million Initial Public Offering HOUSTON, TEXAS, September 20, 2022 – Nexalin Technology, Inc. (the “Company” or “Nexalin”) today announced the closing of its previously announced initial public offering of 2,315,000 units consisting of 2,315,000 shares of its common stock and 2,315,000 accompanying warrants to purchase 2,315,000 share |
|
| September 20, 2022 |
Exhibit 4.1 EXECUTION COMMON STOCK PURCHASE WARRANT AGREEMENT Nexalin technology, inc. THIS COMMON STOCK PURCHASE WARRANT AGREEMENT (the ?Warrant?) dated as of September 16, 2022 is entered into by and between NEXALIN TECHNOLOGY INC., a Delaware corporation (the ?Company?), and Continental Stock Transfer & Trust Company, a New York corporation (the ?Warrant Agent?). WHEREAS, the Company has filed |
|
| September 19, 2022 |
NEXALIN TECHNOLOGY, INC. 2,315,000 Units 424B4 1 nexalintech424b4.htm 424B4 Filed Pursuant to Rule 424(b)(4) Registration No. 333-261989 PROSPECTUS NEXALIN TECHNOLOGY, INC. 2,315,000 Units This is a firm commitment initial public offering of our securities. We are offering 2,315,000 units at an offering price of $4.15 per unit. Each unit is comprised of one share of our common stock and a redeemable warrant to acquire one share of common |
|
| September 16, 2022 |
Underwriting Agreement dated as of September 15, 2022 between the Registrant and Maxim Group LLC EX-1.1 2 nexalintechex1-1.htm EXHIBIT 1.1 Exhibit 1.1 NEXALIN TECHNOLOGY, INC. UNDERWRITING AGREEMENT September 15, 2022 Maxim Group LLC 300 Park Avenue, 16th Floor New York, New York 10022 As Representative of the Underwriters named on Schedule A hereto Ladies and Gentlemen: Nexalin Technology, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated here |
|
| September 16, 2022 |
Other Events, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 15, 2022 NEXALIN TECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-41507 27-5566468 (State or other jurisdiction of incorporation) (Commis |
|
| September 16, 2022 |
Nexalin Technology, Inc. Announces Pricing of $9.6 Million Initial Public Offering Exhibit 99.1 Nexalin Technology, Inc. Announces Pricing of $9.6 Million Initial Public Offering HOUSTON, TEXAS, September 15, 2022 – Nexalin Technology, Inc. (the “Company” or “Nexalin”) today announced the pricing of its initial public offering of 2,315,000 units consisting of 2,315,000 shares of its Common Stock and 2,315,000 accompanying warrants to purchase up to 2,315,000 shares of common sto |
|
| September 15, 2022 |
8-A12B 1 nexalintechinc8a12b.htm 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF l934 Nexalin Technology, Inc. (Exact name of Registrant as specified in its charter) Nevada 27-5566468 (State of incorporation or organization) (I.R.S. Employer I |
|
| September 15, 2022 |
As filed with the Securities and Exchange Commission on September 15, 2022 As filed with the Securities and Exchange Commission on September 15, 2022 Registration No. |
|
| September 15, 2022 |
As filed with the Securities and Exchange Commission on September 15, 2022 As filed with the Securities and Exchange Commission on September 15, 2022 Registration No. |
|
| September 12, 2022 |
Nexalin Technology, Inc. 1776 Yorktown, Suite 550 Houston, TX 77056 (281) 830-8900 CORRESP 1 filename1.htm Nexalin Technology, Inc. 1776 Yorktown, Suite 550 Houston, TX 77056 (281) 830-8900 September 12, 2022 VIA EDGAR Division of Corporate Finance Office of Life Sciences Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attn: Branch Chief Re: Nexalin Technology, Inc. Registration Statement on Form S-1 File No. 333-261989 Ladies and Gentlemen: The Compan |
|
| September 12, 2022 |
CORRESP 1 filename1.htm September 12, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 Re: Nexalin Technology, Inc. Registration Statement on Form S-1 File No. 333-261989 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), Maxim Group LLC, as representative of the se |
|
| August 24, 2022 |
Exhibit 99.1 NEXALIN TECHNOLOGY, INC. CODE OF BUSINESS CONDUCT AND ETHICS INTRODUCTION We are committed to maintaining the highest standards of business conduct and ethics. This Code of Business Conduct and Ethics (this “Code”) reflects the business practices and principles of behavior that support this commitment. We expect every employee, officer and director to read and understand this Code and |
|
| August 24, 2022 |
Compensation Committee Charter Exhibit 99.3 CHARTER OF THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS OF NEXALIN TECHNOLOGY, INC. I. PURPOSES The Compensation Committee (the ?Committee?) is appointed by the Board of Directors (the ?Board?) of NEXALIN TECHNOLOGY, INC., a Delaware corporation (the ?Company?) for the purposes of, among other things, (a) discharging the Board?s responsibilities relating to the compensation of |
|
| August 24, 2022 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF NEXALIN TECHNOLOGY, INC. (A DELAWARE CORPORATION) (As Amended to August 11, 2022) ARTICLE I OFFICES Section 1. Registered Office. The registered office of Nexalin Technology Inc. (the ?Corporation?) in the State of Delaware shall be 1209 Orange Street, in the City of Wilmington, County of New Castle, 19801. Section 2. Other Offices. The Corporation shall |
|
| August 24, 2022 |
Exhibit 99.2 NEXALIN TECHNOLOGY INC. CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS PURPOSE The primary purpose of the Audit Committee (the ?Committee?) of the Board of Directors (the ?Board?) of Nexalin Technology Inc. (the ?Company?) shall be to act on behalf of the Board in fulfilling the Board?s oversight responsibilities with respect to (i) the Company?s corporate accounting and fin |
|
| August 24, 2022 |
As filed with the Securities and Exchange Commission on August 24, 2022 As filed with the Securities and Exchange Commission on August 24, 2022 Registration No. |
|
| August 24, 2022 |
Exhibit 10.12 LOCK-UP AGREEMENT August , 2022 Maxim Group LLC 405 Lexington Avenue New York, NY 10174 Re: Nexalin Technology, Inc. Ladies and Gentlemen: As an inducement to Maxim Group LLC, as representative of the underwriters (the ?Representative?), to execute an underwriting agreement (the ?Underwriting Agreement?) providing for a public offering (the ?Offering?) of securities including the com |
|
| August 24, 2022 |
Nominating and Corporate Governance Committee Charter Exhibit 99.4 CHARTER OF THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS OF NEXALIN TECHNOLOGY, INC. I. PURPOSES The Compensation Committee (the ?Committee?) is appointed by the Board of Directors (the ?Board?) of NEXALIN TECHNOLOGY, INC., a Delaware corporation (the ?Company?) for the purposes of, among other things, (a) discharging the Board?s responsibilities relating to the compensation of |
|
| May 31, 2022 |
Form of Underwriting Agreement between the Company and Maxim Group LLC. EX-1.1 2 nexalintechnologyex1-1.htm EXHIBIT 1.1 Exhibit 1.1 NEXALIN TECHNOLOGY, INC. UNDERWRITING AGREEMENT [●], 2022 Maxim Group LLC 300 Park Avenue, 16th Floor New York, New York 10022 As Representative of the Underwriters named on Schedule A hereto Ladies and Gentlemen: Nexalin Technology, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, |
|
| May 31, 2022 |
Warshaw Burstein, LLP 575 Lexington Avenue New York, NY 10022 (212) 984-7700 www.wbny.com Brian C. Daughney EMAIL: [email protected] DIRECT DIAL: (212) 984-7797 May 31, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Joshua Gorsky Re: Nexalin Technology, Inc. Amendment No. 6 to Registration Statement on Form S-1 |
|
| May 31, 2022 |
As filed with the Securities and Exchange Commission on May 31, 2022 As filed with the Securities and Exchange Commission on May 31, 2022 Registration No. |
|
| May 16, 2022 |
As filed with the Securities and Exchange Commission on May 16, 2022 As filed with the Securities and Exchange Commission on May 16, 2022 Registration No. |
|
| May 16, 2022 |
CORRESP 1 filename1.htm Warshaw Burstein, LLP 575 Lexington Avenue New York, NY 10022 (212) 984-7700 www.wbny.com Brian C. Daughney EMAIL: [email protected] DIRECT DIAL: (212) 984-7797 May 16, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Gary Newberry Terence O'Brien Joshua Gorsky Jeffrey Gabor Re: Nexalin Tech |
|
| April 28, 2022 |
Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Nexalin Technology, Inc. |
|
| April 28, 2022 |
Distribution Authorization Agreement dated as of May 1, 2019 with Wider Come Limited. Exhibit 10.15 Nexalin Technology Inc. (Nexalin) authorizes its Asia Pacific Exclusive Master distributor Wider Come Limited (Wider) to: ? Conduct marketing and sales of Nexalin products in Asia Pacific including the establishment of all pricing stuctrues. ? Recruit and manage other sub-distributors. ? Register all current and new products with Asia Pacific authorities as required. ? Communicate wi |
|
| April 28, 2022 |
As filed with the Securities and Exchange Commission on April 27, 2022 As filed with the Securities and Exchange Commission on April 27, 2022 Registration No. |
|
| April 27, 2022 |
Warshaw Burstein, LLP 575 Lexington Avenue New York, NY 10022 (212) 984-7700 www.wbny.com Brian C. Daughney EMAIL: [email protected] DIRECT DIAL: (212) 984-7797 April 27, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Gary Newberry Terence O'Brien Joshua Gorsky Je?rey Gabor Re: Nexalin Technology, Inc. Amendment |
|
| April 8, 2022 |
Form of Underwriter’s Warrant Agreement (included as Exhibit A to Exhibit 1.1) Exhibit 1.1 NEXALIN TECHNOLOGY, INC. UNDERWRITING AGREEMENT [?], 2022 Maxim Group LLC 405 Lexington Avenue New York, New York 10174 As Representative of the Underwriters named on Schedule A hereto Ladies and Gentlemen: Nexalin Technology, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell an aggregate of [?] units (the ?Unit |
|
| April 8, 2022 |
Amendment to Employment Agreement with David Owens, M.D. Exhibit 10.11 AMENDMENT NO 1 TO EMPLOYMENT AGREMENT BETWEEN DAVID OWENS MD AND NEXALIN TECHNOLOGY INC. This Amendment No. 1 to Employment Agreement is made as of March , 2022 by and between David Owens M.D. (?Executive?) and Nexalin Technology Inc. (the ?Company?). WHEREAS, Executive and the Company executed an Employment Agreement dated as of February 15, 2021 (?Prior Agreement?); and WHEREAS, Ex |
|
| April 8, 2022 |
Promissory Note in favor Mark White dated as of November 1, 2021, as amended Exhibit 10.14 PROMISSORY NOTE November 1, 2021 $200,000 For Value Received, NEXALIN TECHNOLOGY, INC., a Nevada corporation (the ?Maker?) promises to pay to the order of MARK WHITE (the ?Payee?) the principal sum of TWO HUNDRED THOUSAND DOLLARS ($200,000) (the ?Loan?). The entire unpaid balance and interest thereon of the Loan as set forth below shall be due and payable on the earlier to occur of ( |
|
| April 8, 2022 |
As filed with the Securities and Exchange Commission on April 8, 2022 As filed with the Securities and Exchange Commission on April 8, 2022 Registration No. |
|
| April 8, 2022 |
Form of Warrant Agent Agreement between the Company and Continental Stock Transfer & Trust Company Exhibit 4.2 COMMON STOCK PURCHASE WARRANT Nexalin technology, inc. Warrant Shares: Initial Exercise Date: , 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the ?Initial Exe |
|
| April 8, 2022 |
Exhibit 10.13 |
|
| April 8, 2022 |
Exhibit 10.9 US ASIAN CONSULTING GROUP, LLC 32 Camlet Court Roseland, New Jersey 07068 Dated as of March 30, 2022 Nexalin Technologies, Inc. 1776 Yorktown, Suite 550 Houston, Texas 77056 Attn.: Mark White, CEO Re: Deferral of Consulting Fee Ladies and Gentlemen: We refer to the Consulting Agreement, as amended, dated as of May 9, 2018 (?Consulting Agreement?) between US Asian Consulting Group, LLC |
|
| April 8, 2022 |
CORRESP 1 filename1.htm Warshaw Burstein, LLP 575 Lexington Avenue New York, NY 10022 (212) 984-7700 www.wbny.com Brian C. Daughney EMAIL: [email protected] DIRECT DIAL: (212) 984-7797 April 8, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Gary Newberry Terence O'Brien Joshua Gorsky Jeffrey Gabor Re: Nexalin Te |
|
| April 8, 2022 |
Certificate of Incorporation, as amended and as currently in effect. Exhibit 3.1 |
|
| April 8, 2022 |
Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Nexalin Technology, Inc. |
|
| April 8, 2022 |
Exhibit 10.10 SUPPLEMENTARY AGREEMENT NO. 2 FOR JOINT VENTURE AGREEMENT This SUPPLEMENTARY AGREEMENT NO. 2 FOR JOINT VENTURE AGREEMENT is entered into as of the 9th day of March, 2022 by and between NEXALIN TECHNOLOGY, INC. (??Nexalin?) and WIDER COM LIMITED (?Wider?). Nexalin and Wider are sometimes individually referred to as a ??Party? and collectively as the ?Parties?. WHEREAS, the Parties hav |
|
| February 4, 2022 |
EXHIBIT 107 Calculation of Filing Fee Tables S-1 (Form Type) NEXALIN TECHNOLOGY, INC. |
|
| February 4, 2022 |
As submitted to the Securities and Exchange Commission on February 4, 2022 As submitted to the Securities and Exchange Commission on February 4, 2022 Registration No. |
|
| January 31, 2022 |
Agreement between the Company and Maxim Group LLC. EX-1.1 2 e14909ex1-1.htm FORM OF UNDERWRITING AGREEMENT Exhibit 1.1 NEXALIN TECHNOLOGY, INC. UNDERWRITING AGREEMENT [•], 2022 Maxim Group LLC 405 Lexington Avenue New York, New York 10174 As Representative of the Underwriters named on Schedule A hereto Ladies and Gentlemen: Nexalin Technology, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein |
|
| January 31, 2022 |
Employment Agreement between the Company and Marilyn Elson dated as of January 11, 2022 Exhibit 10.8 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (this ?Agreement?) dated as of January 11, 2022 between Marilyn Elson (the ?Executive?) and NEXALIN TECHNOLOGY INC. (the ?Company?). WHEREAS, the Company would like to employ the Executive as its Chief Financial Officer; and WHEREAS, the Company and the Executive desire to provide for the terms and conditions of the future employment of the Ex |
|
| January 31, 2022 |
Exhibit 10.9 Form of Underwriters? Warrants Agreement THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT U |
|
| January 31, 2022 |
As submitted to the Securities and Exchange Commission on January 28, 2022 As submitted to the Securities and Exchange Commission on January 28, 2022 Registration No. |
|
| January 31, 2022 |
Form of Specimen stock certificate evidencing shares of common stock. EX-4.1 3 e14909ex4-1.htm FORM OF SPECIMEN STOCK CERTIFICATE EVIDENCING SHARES OF COMMON STOCK Exhibit 4.1 NUMBER [] [] SHARES SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP 65345B 201 NEXALIN TECHNOLOGY, INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE COMMON STOCK This Certifies that is the owner of FULLY PAID AND NON-ASSESSABLE SHARES OF THE PAR VALUE OF $0.001 EACH OF THE COMMON STOCK OF NE |
|
| January 31, 2022 |
Warshaw Burstein, LLP 575 Lexington Avenue New York, NY 10022 (212) 984-7700 www.wbny.com MARTIN S. SIEGEL EMAIL: [email protected] DIRECT DIAL: (212) 984-7741 January 28, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Gary Newberry Terence O'Brien Joshua Gorsky Jeffrey Gabor Re: Nexalin Technology, Inc. Registrati |
|
| January 4, 2022 |
Advisor Agreement with Gian Domenico Trombetta dated December 24, 2021. Exhibit 10.7 NEXALIN TECHNOLOGY, INC. 1776 YORKTOWN, SUITE 550 HOUSTON, TX 77056 Mr. Gian Domenic Trombetta Dear Gian Trombetta, Your service will be for a term of one (1) year, which term may be extended for additional one (1) year terms upon our mutual agreement. As consideration for your service on the Board of Advisors, you shall receive shares of our common stock worth $80,000 based upon the |
|
| January 4, 2022 |
Employment Agreement between the Company and Mark White dated as of February 15, 2021. Exhibit 10.2 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (this “Agreement”) dated as of February 15, 2021 between MARK WHITE (the “Executive”) and NEXALIN TECHNOLOGY INC. (the “Company”). WHEREAS, the Company would like to employ the Executive as its Chief Executive Officer; and WHEREAS, the Company and the Executive desire to provide for the terms and conditions of the future employment of the Exec |
|
| January 4, 2022 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF NEXALIN TECHNOLOGY, INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of Nexalin Technology Inc. (the “Corporation”) in the State of Delaware shall be 1209 Orange Street, in the City of Wilmington, County of New Castle, 19801. Section 2. Other Offices. The Corporation shall also have and maintain an office |
|
| January 4, 2022 |
Advisor Agreement with Tucker Anderson dated as of December 24, 2021. EX-10.6 9 e14815ex10-6.htm ADVISOR AGREEMENT Exhibit 10.6 NEXALIN TECHNOLOGY, INC. 1776 YORKTOWN, SUITE 550 HOUSTON, TX 77056 Mr. Tucker Anderson Dear Tucker: Nexalin Technology, Inc. (the “Company”) is pleased to welcome you to serve on its Board of Advisors. We appreciate your willingness to accept this position, and we look forward to your valuable contributions. Your service will be for a term |
|
| January 4, 2022 |
Certificate of Incorporation, as Exhibit 3.1 |
|
| January 4, 2022 |
Agreement between the Company and David Owens, M.D. dated as of February 15, 2021 EX-10.3 6 e14815ex10-3.htm EMPLOYMENT AGREEMENT Exhibit 10.3 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (this “Agreement”) dated as of February 15, 2021 between DAVID OWENS, MD (the “Executive”) and NEXALIN TECHNOLOGY INC. (the “Company”). WHEREAS, the Company would like to employ the Executive as its Chief Medical Officer; and WHEREAS, the Company and the Executive desire to provide for the terms |
|
| January 4, 2022 |
Quality Assurance Agreement between the Company and Apical Instruments dated December 31, 2020. NEX-CNT-00016 Revision 1 Exhibit 10.4 Apical Quality Agreement This Quality Agreement ("Agreement") is made on 12/21/2020 by and between Nexalin and Apical Instruments ("Apical"). 1 Introduction The objectives of this Quality Assurance Agreement are to: • establish a collaborative partnership • define responsibilities • assure that all quality requirements concerning the Nexalin Products are met • |
|
| January 4, 2022 |
Warshaw Burstein, LLP Kyle Taylor 575 Lexington Avenue Counsel New York, NY 10022 (212) 984-7797 (212) 984-7700 ktaylor@wbny. |
|
| January 4, 2022 |
As submitted to the Securities and Exchange Commission on January 3, 2022 As submitted to the Securities and Exchange Commission on January 3, 2022 Registration No. |
|
| January 4, 2022 |
Advisor Agreement with Leonard Osser dated as of December 22,2021. EX-10.5 8 e14815ex10-5.htm ADVISOR AGREEMENT Exhibit 10.5 NEXALIN TECHNOLOGY, INC. l 776 YORKTOWN, SUITE 550 HOUSTON, TX 77056 Mr. Leonard Osser Dear Len: Nexalin Technology, lnc. (the "Company") is pleased to welcome you to serve on its Board of Advisors. We appreciate your willingness to accept this position, and we look forward to your valuable contributions. Your service will be for a tenn of |
|
| January 4, 2022 |
Exhibit 10.1 JOINT VENTURE AGREEMENT JOINT VENTURE AGREEMENT, dated as of September 21, 2018 (this ?Agreement?), is by and between Nexalin Technology, Inc., a Nevada corporation (?Nexalin?), and [Wider come Limited], a company formed under the laws of [Hong Kong] (?Wider??,and together with Nexalin, collectively, the ?parties? and each, a ?party?). RECITALS: WHEREAS, the parties desire to establis |
|
| December 8, 2021 |
As confidentially submitted to the Securities and Exchange Commission on December 7, 2021. |
|
| December 8, 2021 |
Warshaw Burstein, LLP Kyle Taylor 575 Lexington Avenue Counsel New York, NY 10022 (212) 984-7797 (212) 984-7700 ktaylor@wbny. |
|
| November 2, 2021 |
EX-10.1 2 filename2.htm Exhibit 10.1 JOINT VENTURE AGREEMENT JOINT VENTURE AGREEMENT, dated as of September 21, 2018 (this “Agreement’), is by and between Nexalin Technology, Inc., a Nevada corporation (“Nexalin”), and [Wider come Limited], a company formed under the laws of [Hong Kong] (‘Wider’’,and together with Nexalin, collectively, the “parties” and each, a “party”). RECITALS: WHEREAS, the pa |
|
| November 2, 2021 |
EX-10.3 4 filename4.htm Exhibit 10.3 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (this “Agreement”) dated as of February 15, 2021 between DAVID OWENS, MD (the “Executive”) and NEXALIN TECHNOLOGY INC. (the “Company”). WHEREAS, the Company would like to employ the Executive as its Chief Medical Officer; and WHEREAS, the Company and the Executive desire to provide for the terms and conditions of the fu |
|
| November 2, 2021 |
Exhibit 10.2 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (this “Agreement”) dated as of February 15, 2021 between MARK WHITE (the “Executive”) and NEXALIN TECHNOLOGY INC. (the “Company”). WHEREAS, the Company would like to employ the Executive as its Chief Executive Officer; and WHEREAS, the Company and the Executive desire to provide for the terms and conditions of the future employment of the Exec |
|
| November 2, 2021 |
COVER 160 filename160.htm Warshaw Burstein, LLP Kyle Taylor 575 Lexington Avenue Counsel New York, NY 10022 (212) 984-7797 (212) 984-7700 [email protected] www.wbny.com November 1, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Gary Newberry Terence O’Brien Deanna Virginio Jeffrey Gabor Re: Nexalin Technology, Inc |
|
| November 2, 2021 |
As confidentially submitted to the Securities and Exchange Commission on November 1, 2021. |
|
| November 2, 2021 |
EX-10.4 5 filename5.htm Exhibit 10.4 NEX-CNT-00016 Revision 1 Apical Quality Agreement This Quality Agreement (“Agreement”) is made on 12/21/2020 by and between Nexalin and Apical Instruments (“Apical”). 1 Introduction The objectives of this Quality Assurance Agreement are to: • establish a collaborative partnership • define responsibilities • assure that all quality requirements concerning the Ne |
|
| September 17, 2021 |
DRS 1 filename1.htm As confidentially submitted to the Securities and Exchange Commission on September 17, 2021. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEME |
